Spironolactone Tablet, Coated
Product Images NDC 69584-853

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 69584-853). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Oxford Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg (100mg)

Label for Spironolactone Tablets USP 100 mg, oral coated tablets, manufactured by Oxford Pharmaceuticals, LLC. The label indicates the package contains 100 tablets, with the NDC 69584-854-10, and includes storage instructions and a serialization area.*

FDA Label Image

25 mg Label (25mg)

Spironolactone 25 mg coated oral tablets packaging label by Oxford Pharmaceuticals, LLC. The label displays the drug name, strength (25 mg), quantity (100 tablets), and NDC code 69584-852-10. Manufacturer information lists Oxford Pharmaceuticals, LLC in Birmingham, Alabama. The label includes dosing and storage instructions as well as a designated serialization area.*

FDA Label Image

50 mg Label (50mg)

Label for Spironolactone tablets, USP 50 mg, in a bottle of 100 coated oral tablets. The product is manufactured by Oxford Pharmaceuticals, LLC. The label includes the NDC 69584-853-10, the dosage strength, and storage instructions.*

FDA Label Image

Figure 1 (Figure1)

A survival probability Kaplan-Meier curve showing patient outcomes over 48 months comparing Spironolactone versus placebo groups. The solid line represents placebo and the dashed line represents Spironolactone, with the Spironolactone group showing higher survival probability over time. The graph includes number of patients: 822 for Spironolactone and 841 for placebo. A log-rank test indicates statistical significance with p < 0.001.*

FDA Label Image

Figure 2 (Figure2)

A forest plot chart showing hazard ratios (HR) and 95% confidence intervals (CI) for various patient subgroups in a clinical study comparing Spironolactone to placebo. Subgroups include age, sex, race, LVEF percentage, heart failure type, NYHA class, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The chart indicates the number of patients and percentage within each subgroup, with an axis indicating if Spironolactone or placebo is favored.*

FDA Label Image

20 (Spironolactone Tablets Usp 1)

Chemical structure of spironolactone, a steroid derivative with lactone and thioacetate functional groups, depicted in a two-dimensional molecular diagram.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.